

Putting NICE guidance into practice

Costing statement: Dual-chamber pacemakers

Implementing the NICE guidance on Dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block (part review of technology appraisal guidance 88) (TA324)

Published: November 2014

1 Introduction

- 1.1 The guidance on 'Dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block (part review of technology appraisal guidance 88)' (NICE technology appraisal guidance 324) is unlikely to result in a significant change in resource use in the NHS.
- 1.2 The guidance states that: Dual-chamber pacemakers are recommended as an option for treating symptomatic bradycardia due to sick sinus syndrome without atrioventricular block.
- 1.3 The purpose of the part-review is to update the recommendation in NICE technology appraisal guidance 88 (TA88) for people with symptomatic bradycardia and no evidence of atrioventricular block. TA88 recommended single-chamber atrial pacemakers for treating sick sinus syndrome in people in whom, after full evaluation, there was no evidence of impaired atrioventricular conduction.
- 1.4 The commissioner for this technology is clinical commissioning groups. Providers are healthcare providers with cardiology services.

2 Patient numbers affected

- 2.1 During 2012-13 in England, more than 20,000 people had a single- or dual-chamber pacemaker implanted. Sick sinus syndrome was the fourth most prevalent primary diagnosis (9.5%) for implantation of a single- or dual-chamber pacemaker. Among patients with a primary diagnosis of sick sinus syndrome (2,490 patients) 67.5% had implantation of a dual-chamber pacemaker, 14.8% had a single-chamber pacemaker implanted, and 2.2% had a reoperation of an existing implanted pacemaker¹.

¹ [Assessment Group Report](#): Dual-chamber pacemakers for treating symptomatic bradycardia due to sick sinus syndrome without atrioventricular block, part review of Technology Appraisal 88. BMJ Technology Assessment Group (July 2014). The text can be found in the executive summary on page 15. National costing statement: Dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block (part review of technology appraisal guidance 88) (November 2014)

3 Resource impact

- 3.1 The Committee concluded that in clinical practice, dual-chamber rather than single-chamber atrial devices were already being implanted for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block in most of the patients². Therefore, we do not anticipate a significant impact on resources.

4 Conclusion

- 4.1 No significant change in practice is anticipated as a result of implementing this guidance. Therefore, we do not anticipate a significant impact on resources.

² [Final Appraisal Determination](#). National Institute for Health and Care Excellence (November 2014). National costing statement: Dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block (part review of technology appraisal guidance 88) (November 2014)